OR WAIT null SECS
March 30, 2023
Takeda received approval in Japan for a subcutaneous injection formulation of Entyvio (vedolizumab) for treating ulcerative colitis.
Takeda plans to build a new facility in Osaka, Japan, for the manufacture of plasma-derived therapies.
Roche and Lilly will collaborate on the development of Roche Diagnostics’ Elecsys Amyloid Plasma Panel.
March 24, 2023
Moderna and Generation Bio have announced a strategic collaboration to develop non-viral genetic medicines.
Curia is collaborating with Corning to advance biopharmaceutical continuous-flow development and manufacturing programs.
March 22, 2023
Under a new partnership, Invitae and Deerfield Management will harness genetic and clinical testing data from patients to discover potential novel therapeutics for treating rare diseases.
The decision was based on results from the PROpel Phase III trial.
This approval makes the drug the first and only targeted medicine indicated to treat this population of children in Europe and the United States.
March 21, 2023
Sanofi intends to cut its US list price for Lantus (insulin glargine injection) by 78% and cap out-of-pocket costs at $35 for all patients with commercial insurance.
BioNTech will receive an exclusive worldwide license from OncoC4 to develop and commercialize its anti-CTLA-4 mAb candidate for solid tumor indications.